SHAREHOLDER ALERT: BIDU FSLY ODT: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines

NEW YORK, NY / ACCESSWIRE / October 11, 2020 / The Law Offices of Vincent Wong announce that class actions have commenced on behalf of certain shareholders in the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff. There will be no obligation or cost to you.

Baidu, Inc. (NASDAQ:BIDU)

If you suffered a loss, contact us at: http://www.wongesq.com/pslra-1/baidu-inc-loss-submission-form-2?prid=9998&wire=1
Lead Plaintiff Deadline: October 19, 2020
Class Period: April 8, 2016 - August 13, 2020

Allegations against BIDU include that: (1) Baidu misrepresented the financial and business condition of iQIYI; (2) iQIYI had inadequate controls; and (3) as a result, Defendants' public statements were materially false and/or misleading at all relevant times.

Fastly, Inc. (NYSE:FSLY)

If you suffered a loss, contact us at: http://www.wongesq.com/pslra-1/fastly-inc-loss-submission-form?prid=9998&wire=1
Lead Plaintiff Deadline: October 26, 2020
Class Period: May 6, 2020 - August 5, 2020

Allegations against FSLY include that: (1) Fastly's largest customer was ByteDance, operator of TikTok, which was known to have serious security risks and was under intense scrutiny by U.S. officials; (2) there was a material risk that Fastly's business would be adversely impacted should any adverse actions be taken against ByteDance or TikTok by the U.S. government; and (3) as a result, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

Odonate Therapeutics, Inc. (NASDAQ:ODT)

If you suffered a loss, contact us at: http://www.wongesq.com/pslra-1/odonate-therapeutics-inc-loss-submission-form?prid=9998&wire=1
Lead Plaintiff Deadline: November 16, 2020
Class Period: December 7, 2017 - April 21, 2020

Allegations against ODT include that: (i) the Company's orally administered chemotherapy agent, tesetaxel, was not as safe or well-tolerated as the Company had led investors to believe; (ii) consequently, tesetaxel's commercial viability as a cancer treatment was overstated; and (iii) as a result, the Company's public statements were materially false and misleading at all relevant times.

To learn more contact Vincent Wong, Esq. either via email vw@wongesq.com or by telephone at 212.425.1140.

Vincent Wong, Esq. is an experienced attorney who has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
Vincent Wong, Esq.
39 East Broadway
Suite 304
New York, NY 10002
Tel. 212.425.1140
Fax. 866.699.3880
E-Mail: vw@wongesq.com

SOURCE: The Law Offices of Vincent Wong



View source version on accesswire.com:
https://www.accesswire.com/610025/SHAREHOLDER-ALERT-BIDU-FSLY-ODT-The-Law-Offices-of-Vincent-Wong-Reminds-Investors-of-Important-Class-Action-Deadlines

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.